Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 19/20 | 1.00 |
| ▸ | ERBB2 | P04626 | 16/20 | 1.00 |
| ▸ | GAK | O14976 | 2/20 | 1.00 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.74 |
| ▸ | SRC | P12931 | 1/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6379850 | 0.94 | EGFR (1.00) | EGFRERBB2GAKMAP2K1SRC | |
| SCHEMBL6380499 | 0.94 | EGFR (1.00) | EGFRERBB2GAKMAP2K1SRC | |
| SCHEMBL1893937 | 0.92 | EGFR (0.84) | EGFRERBB2GAK | |
| SCHEMBL6381277 | 0.89 | EGFR (1.00) | EGFRERBB2GAK | |
| SCHEMBL95052 | 0.89 | EGFR (1.00) | EGFRERBB2GAK | |
| SCHEMBL6380173 | 0.89 | EGFR (1.00) | EGFRERBB2GAKSRC | |
| SCHEMBL6381535 | 0.88 | EGFR (1.00) | EGFRERBB2GAKMAP2K1SRC | |
| SCHEMBL6381446 | 0.88 | EGFR (1.00) | EGFRERBB2GAKMAP2K1SRC | |
| SCHEMBL6383928 | 0.87 | EGFR (0.85) | EGFRERBB2GAK | |
| SCHEMBL8142302 | 0.87 | EGFR (0.77) | EGFRERBB2GAK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1263503-B1 | USE OF CYANOQUINOLINES FOR TREATING OR INHIBITING COLONIC POLYPS | WYETH CORP (US) | 2005-11-02 | — | — | EP | claimed |
| EP-0973746-B1 | SUBSTITUTED 3-CYANO QUINOLINES | WYETH CORP (US) | 2003-09-24 | — | — | EP | claimed |
| JP-2003526686-A | — | — | 2003-09-09 | — | — | JP | claimed |
| EP-1263503-A2 | USE OF CYANOQUINOLINES FOR TREATING OR INHIBITING COLONIC POLYPS | AMERICAN CYANAMID COMPANY (US) | 2002-12-11 | — | — | EP | claimed |
| US-6384051-B1 | ANTITUMOR AGENTS | AMERICAN CYANAMID COMPANY | 2002-05-07 | — | — | US | claimed |
| WO-2001068186-A2 | USE OF CYANOQUINOLINES FOR TREATING OR INHIBITING COLONIC POLYPS | AMERICAN CYANAMID COMPANY (US) | 2001-09-20 | — | — | WO | claimed |
| US-6002008-A | Substituted 3-cyano quinolines | AMERICAN CYANAMID COMPANY | 1999-12-14 | — | — | US | claimed |
| US-9977024-B2 | Targeted covalent probes and inhibitors of proteins containing redox-sensitive cysteines | THE SCRIPPS RESEARCH INSTITUTE (US) | 2018-05-22 | — | — | US | disclosed |
| US-20160195532-A1 | Targeted Covalent Probes and Inhibitors of Proteins Containing Redox-Sensitive Cysteines | THE SCRIPPS RESEARCH INSTITUTE | 2016-07-07 | — | — | US | disclosed |
| US-20160195532-A1 | Targeted Covalent Probes and Inhibitors of Proteins Containing Redox-Sensitive Cysteines | THE SCRIPPS RESEARCH INSTITUTE | 2016-07-07 | — | — | US | disclosed |
| US-9271987-B2 | Methods and compositions for treating Alzheimer's disease | COLD SPRING HARBOR LABORATORY (US) | 2016-03-01 | — | — | US | disclosed |
| CN-103547289-A | Methods and compositions for treating alzheimer's disease | COLD SPRING HARBOR LAB | 2014-01-29 | — | — | CN | disclosed |
| EP-2667896-A2 | METHODS AND COMPOSITIONS FOR TREATING ALZHEIMER'S DISEASE | Cold Spring Harbor Laboratory (US) | 2013-12-04 | — | — | EP | disclosed |
| EP-1263503-A2 | USE OF CYANOQUINOLINES FOR TREATING OR INHIBITING COLONIC POLYPS | AMERICAN CYANAMID COMPANY (US) | 2002-12-11 | — | — | EP | disclosed |
| US-6384051-B1 | ANTITUMOR AGENTS | AMERICAN CYANAMID COMPANY | 2002-05-07 | — | — | US | disclosed |
| WO-2001068186-A2 | USE OF CYANOQUINOLINES FOR TREATING OR INHIBITING COLONIC POLYPS | AMERICAN CYANAMID COMPANY (US) | 2001-09-20 | — | — | WO | disclosed |
| CN-1259125-A | Substituted 3-cyanoquinolines | AMERICAN CYANAMID CO (US) | 2000-07-05 | — | — | CN | disclosed |
| EP-0973746-A1 | SUBSTITUTED 3-CYANO QUINOLINES | American Cyanamid Company (US) | 2000-01-26 | — | — | EP | disclosed |
| US-6002008-A | Substituted 3-cyano quinolines | AMERICAN CYANAMID COMPANY | 1999-12-14 | — | — | US | disclosed |
| WO-1998043960-A1 | SUBSTITUTED 3-CYANO QUINOLINES | AMERICAN CYANAMID COMPANY (US) | 1998-10-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160195532-A1 | Targeted Covalent Probes and Inhibitors of Proteins Containing Redox-Sensitive Cysteines | PTMS, RSU1, QSOX1 | EGFR 1430/4885ERBB2 325/4885GAK 2106/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.